U.S. government-funded HIV/AIDS research sites in Africa are joining an ongoing clinical trial for an investigational tuberculosis (TB) vaccine for infants, according to a National Institutes of Health (NIH) statement. The new vaccine, labeled AERAS-402/Crucell Ad35, is a booster shot administered to infants ages 16 months to 26 months as a follow-up to the standard Bacille Calmette-Guérin (BCG) vaccine. Unlike the BCG vaccine, which is not recommended for HIV-positive infants, the investigational vaccine does not contain live TB virus, and previous trials indicate that it's safe for HIV-positive adults.

To read the NIH statement, click here.